復宏漢霖(02696.HK)自主研發HLX6018注射液臨床試驗申請獲批

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

復宏漢霖(02696.HK)自主研發HLX6018注射液臨床試驗申請獲批

阿思達克 03-13 01:30

復宏漢霖(02696.HK)公布，公司自主研發的HLX6018(重組抗GARP/TGF-β1人源化單克隆抗體注射液)用於特發性肺纖維化治療的臨床試驗申請獲國家藥品監督管理局批准。

復宏漢霖(02696.HK)

Relevant Stocks

復宏漢霖(02696.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

復宏漢霖(02696.HK)自主研發HLX6018注射液臨床試驗申請獲批

Services

About Us

Agreement Statement